Clinical Trials

Disease Plaque Psoriasis
Title A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar adalimumab (GP2017) and Humira® in patients with moderate to severe chronic plaque-type psoriasis
Inclusion* Must have a clinical diagnosis of chronic plaque psoriasis for at least 6 months and must have received, or must be a candidate for, phototherapy or systemic treatment for plaque psoriasis
Exclusion Previous exposure to Humira®
Study Contact dermpharm@nyumc.org
Principal Investigator Andrea L. Neimann, MD, MSCE
Objective This study is designed to investigate if GP2017 is as effective as Humira® in treating your skin condition and if it has similar side effects as Humira®
Status RECRUITING
Age Requirement 18 years+
Gender males and females

 

Disease Plaque Psoriasis
Title A prospective, observational study to estimate the proportion of subjects with plaque psoriasis who achieve complete clearance on biologics
Inclusion* Patient must be starting treatment with a biologic agent approved for moderate to severe psoriasis either for the first time (biologic treatment-naïve) or in the course of switching to a different biologic agent
Exclusion Participating in a clinical trial utilizing an investigational agent in the 3 months prior to the first biologic dose
Study Contact dermpharm@nyumc.org
Principal Investigator Andrea L. Neimann, MD, MSCE
Objective The purpose of this study is to learn more about the effectiveness of biologic drugs in people with moderate to severe plaque psoriasis. Biologic drugs, or "biologics", are a relatively new class of treatment for psoriasis which act on specific parts of the immune system thought to be involved in the disease.
Status RECRUITING
Age Requirement 18 years+
Gender males and females

 

 Disease Atopic Dermatitis
Title A phase II, randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of CIM331 in atopic dermatitis patients who are inadequately controlled by or intolerant to topical therapy
Inclusion* A diagnosis of moderate to severe atopic dermatitis who are inadequately controlled by or intolerant to topical therapy
Study Contact dermpharm@nyumc.org
Principal Investigator Andrea L. Neimann, MD, MSCE
Objective This study is being carried out to see if the new experimental drug called CIM331 is safe and effective in subjects with moderate to severe atopic dermatitis.
Status RECRUITING
Age Requirement 18-65 years of age
Gender males and females*

 

 *: Required for all studies: females of childbearing age must have a negative pregnancy test at screening and agree to use at least two forms of contraception during their participation in the study.

For complete information regarding inclusion and exclusion criteria, please call 212-263-5244 or email Elizabeth.Camacho@nyumc.org